The global chronic kidney disease drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of chronic kidney disease and the rising awareness about its treatment. Chronic kidney disease is a condition in which one or both kidneys are damaged and cannot filter blood as well as they should, leading to high levels of waste products in the body. It can lead to serious health problems such as heart failure, anemia, and high blood pressure. The global chronic kidney disease drugs market has been segmented on the basis of type into ACE inhibitors, calcium channel blockers, beta blockers; by application into hospitals and specialty clinics; by region into North America (NA), Latin America (LA), Europe (EU), Asia Pacific (APAC) and Middle East & Africa (MEA).
North America accounted for over 40% share in 2017 owing to higher prevalence rates among elderly population coupled with increased awareness about its treatment options among patients suffering from chronic kidney diseases. In addition, there are various government initiatives for promoting research on new treatments for chronic renal diseases which will further boost growth prospects in this region during the forecast period.
In Latin America region due to lack of awareness about diagnosis and treatment options coupled with low healthcare expenditure per capita have led it account for less than 10% share in 2017 but it is expected that these factors will change over time which will result in significant growth prospects during forecast period owing to increasing number of patients suffering from chronic renal diseases across Latin American countries such as Brazil who are likely going undergo dialysis treatments due their deteriorating health conditions.
Some Of The Growth Factors Of This Market:
- Chronic kidney diseases are caused due to various factors such as diabetes mellitus, hypertension, obesity, and high cholesterol levels in blood which leads to progressive loss of renal function over time leading to end-stage renal disease (ESRD).
- Chronic kidney diseases are associated with increased risk for cardiovascular events such as heart attack or stroke which can lead to death or disability in patients suffering from this condition; hence there is an increased need for early diagnosis and treatment of these conditions before they progress into ESRD stage where dialysis or transplantation becomes necessary for survival of the patient 5) The global population aging trend coupled with lifestyle changes such as sedentary lifestyles and unhealthy diets will drive the demand for chronic kidney disease drugs in coming years.
Industry Growth Insights published a new data on “Chronic Kidney Disease Drugs Market”. The research report is titled “Chronic Kidney Disease Drugs Market research by Types (ACE Inhibitors, Calcium Channel Blockers, Beta Blockers, Others), By Applications (Hospitals, Specialty Clinics), By Players/Companies Keryx Biopharmaceuticals, Inc, Kissei Pharmaceutical Co., Ltd, AbbVie, GlaxoSmithKline, Sanofi, F. Hoffmann-La Roche Ltd, Pfizer, AstraZeneca, Amgen, Teva Pharmaceutical Industries”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Chronic Kidney Disease Drugs Market Research Report
By Type
ACE Inhibitors, Calcium Channel Blockers, Beta Blockers, Others
By Application
Hospitals, Specialty Clinics
By Companies
Keryx Biopharmaceuticals, Inc, Kissei Pharmaceutical Co., Ltd, AbbVie, GlaxoSmithKline, Sanofi, F. Hoffmann-La Roche Ltd, Pfizer, AstraZeneca, Amgen, Teva Pharmaceutical Industries
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Chronic Kidney Disease Drugs Market Report Segments:
The global Chronic Kidney Disease Drugs market is segmented on the basis of:
Types
ACE Inhibitors, Calcium Channel Blockers, Beta Blockers, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Specialty Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Keryx Biopharmaceuticals, Inc
- Kissei Pharmaceutical Co., Ltd
- AbbVie
- GlaxoSmithKline
- Sanofi
- F. Hoffmann-La Roche Ltd
- Pfizer
- AstraZeneca
- Amgen
- Teva Pharmaceutical Industries
Highlights of The Chronic Kidney Disease Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ACE Inhibitors
- Calcium Channel Blockers
- Beta Blockers
- Others
- By Application:
- Hospitals
- Specialty Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chronic Kidney Disease Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chronic kidney disease drugs are medications that help to improve the function of the kidneys. These medications can be used to treat a variety of symptoms, including an increase in blood pressure, difficulty urinating, and fatigue.
Some of the major players in the chronic kidney disease drugs market are Keryx Biopharmaceuticals, Inc, Kissei Pharmaceutical Co., Ltd, AbbVie, GlaxoSmithKline, Sanofi, F. Hoffmann-La Roche Ltd, Pfizer, AstraZeneca, Amgen, Teva Pharmaceutical Industries.
The chronic kidney disease drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Chronic Kidney Disease Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Chronic Kidney Disease Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Chronic Kidney Disease Drugs Market - Supply Chain
4.5. Global Chronic Kidney Disease Drugs Market Forecast
4.5.1. Chronic Kidney Disease Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Chronic Kidney Disease Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Chronic Kidney Disease Drugs Market Absolute $ Opportunity
5. Global Chronic Kidney Disease Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Chronic Kidney Disease Drugs Market Size and Volume Forecast by Type
5.3.1. ACE Inhibitors
5.3.2. Calcium Channel Blockers
5.3.3. Beta Blockers
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Chronic Kidney Disease Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Chronic Kidney Disease Drugs Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Specialty Clinics
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Chronic Kidney Disease Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Chronic Kidney Disease Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Chronic Kidney Disease Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Chronic Kidney Disease Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Chronic Kidney Disease Drugs Demand Share Forecast, 2019-2026
9. North America Chronic Kidney Disease Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Chronic Kidney Disease Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Chronic Kidney Disease Drugs Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Specialty Clinics
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Chronic Kidney Disease Drugs Market Size and Volume Forecast by Type
9.7.1. ACE Inhibitors
9.7.2. Calcium Channel Blockers
9.7.3. Beta Blockers
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Chronic Kidney Disease Drugs Demand Share Forecast, 2019-2026
10. Latin America Chronic Kidney Disease Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Chronic Kidney Disease Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Chronic Kidney Disease Drugs Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Chronic Kidney Disease Drugs Market Size and Volume Forecast by Type
10.7.1. ACE Inhibitors
10.7.2. Calcium Channel Blockers
10.7.3. Beta Blockers
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Chronic Kidney Disease Drugs Demand Share Forecast, 2019-2026
11. Europe Chronic Kidney Disease Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Chronic Kidney Disease Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Chronic Kidney Disease Drugs Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Chronic Kidney Disease Drugs Market Size and Volume Forecast by Type
11.7.1. ACE Inhibitors
11.7.2. Calcium Channel Blockers
11.7.3. Beta Blockers
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Chronic Kidney Disease Drugs Demand Share, 2019-2026
12. Asia Pacific Chronic Kidney Disease Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Chronic Kidney Disease Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Chronic Kidney Disease Drugs Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Chronic Kidney Disease Drugs Market Size and Volume Forecast by Type
12.7.1. ACE Inhibitors
12.7.2. Calcium Channel Blockers
12.7.3. Beta Blockers
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Chronic Kidney Disease Drugs Demand Share, 2019-2026
13. Middle East & Africa Chronic Kidney Disease Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Chronic Kidney Disease Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Chronic Kidney Disease Drugs Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Chronic Kidney Disease Drugs Market Size and Volume Forecast by Type
13.7.1. ACE Inhibitors
13.7.2. Calcium Channel Blockers
13.7.3. Beta Blockers
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Chronic Kidney Disease Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Chronic Kidney Disease Drugs Market: Market Share Analysis
14.2. Chronic Kidney Disease Drugs Distributors and Customers
14.3. Chronic Kidney Disease Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Keryx Biopharmaceuticals, Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Kissei Pharmaceutical Co., Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. AbbVie
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. GlaxoSmithKline
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sanofi
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. F. Hoffmann-La Roche Ltd
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Pfizer
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. AstraZeneca
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Amgen
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Teva Pharmaceutical Industries
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
